

**Priority question for written answer P-000064/2022
to the Commission**
Rule 138
Francesca Donato (NI)

Subject: Use of molnupiravir and remdesivir

In November 2021, the European Medicines Agency (EMA) issued advice to the countries that have decided to use Lagevrio (molnupiravir) to treat COVID-19 patients upon symptom onset, despite the fact that the drug is not currently authorised in the EU.

The following month, the EMA issued guidance on the use of remdesivir, which has been authorised since July 2020.

Recently, AIFA, the Italian Medicines Agency, gave the green light in Italy for molnupiravir and remdesivir to be used to treat COVID-19 patients with concurrent risk factors.

However, many scientists were opposed to the approval of these drugs. They objected to molnupiravir because it has mutagenic potential, is not very effective (reducing hospitalisations by only 30%) and could cause infinite dangerous variants with devastating effects. Many concerns also surround the use of remdesivir on account of its serious side effects and low efficacy.

In the light of the above:

1. Will the Commission refuse to authorise the use of molnupiravir and revoke its authorisation of remdesivir?
2. Will it warn the Member States of the serious risks associated with the use of largely ineffective and potentially harmful drugs like molnupiravir and remdesivir?